Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Debt to Equity (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Debt to Equity for 16 consecutive years, with $2.41 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity rose 316.61% to $2.41 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.41, a 316.61% increase, with the full-year FY2024 number at $0.58, up 16.61% from a year prior.
  • Debt to Equity was $2.41 for Q3 2025 at Harvard Bioscience, up from $2.22 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.42 in Q1 2025 to a low of $0.5 in Q4 2023.
  • A 5-year average of $0.86 and a median of $0.58 in 2024 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: dropped 23.78% in 2023, then skyrocketed 368.38% in 2025.
  • Harvard Bioscience's Debt to Equity stood at $0.58 in 2021, then increased by 11.88% to $0.65 in 2022, then dropped by 22.83% to $0.5 in 2023, then grew by 16.61% to $0.58 in 2024, then skyrocketed by 313.83% to $2.41 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Debt to Equity are $2.41 (Q3 2025), $2.22 (Q2 2025), and $2.42 (Q1 2025).